10/29/2024 | Press release | Distributed by Public on 10/29/2024 04:48
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) reported financial results for the third quarter of 2024 and raised its full-year 2024 guidance (1) for both Revenues and Adjusted (2) diluted EPS.
The third-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer's R&D pipeline can be found at www.pfizer.com.
EXECUTIVE COMMENTARY
Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: "We delivered another strong quarter of results as we continued to execute with discipline, strengthen our commercial position and advance our pipeline. I am pleased with the performance of our product portfolio in the third quarter as we continued to achieve exceptional growth with our Oncology products, including strong revenue growth contributions from Padcev, Xtandi, Lorbrena and Braftovi/Mektovi, and as we delivered on heightened demand for Paxlovid during the recent COVID-19 wave.
"Our performance through the first three quarters of the year is the result of our focus on our most important strategic priorities. I'm confident that we will deliver on our financial commitments in 2024 and that we are well positioned to continue advancing scientific breakthroughs meaningful to our patients and our company, as well as creating long-term shareholder value, in the years to come."
David Denton, Chief Financial Officer and Executive Vice President, stated: "We are extremely pleased with the strong 14% operational revenue growth of Pfizer's non-COVID products in the third quarter. This follows our strong first-half performance, which demonstrates our continued focus on commercial execution and confidence in our ability to deliver on our financial guidance this year. Importantly, we believe our ongoing cost reduction efforts set the company on a path toward future margin expansion."
OVERALL RESULTS
In the first quarter of 2024, Pfizer reclassified royalty income (substantially all of which is related to our Biopharma segment) from Other (income)/deductions--net to revenues and began presenting Royalty revenues as a separate line item within Total revenues in our consolidated statements of operations. Prior-period amounts have been recast to conform to the current presentation.
Some amounts in this press release may not add due to rounding. All percentages have been calculated using unrounded amounts. References to operational variances pertain to period-over-period changes that exclude the impact of foreign exchange rates (6) .
Results for the third quarter and first nine months of 2024 and 2023 (7) are summarized below.
($ in millions, except per share amounts) |
Third-Quarter |
Nine Months |
|||||||||
2024 |
2023 |
Change |
2024 |
2023 |
Change |
||||||
Revenues |
$ 17,702 |
$ 13,491 |
31% |
$ 45,864 |
$ 44,984 |
2% |
|||||
Reported (4) Net Income/(Loss) |
4,465 |
(2,382) |
* |
7,621 |
5,488 |
39% |
|||||
Reported (4) Diluted EPS/(LPS) |
0.78 |
(0.42) |
* |
1.34 |
0.96 |
39% |
|||||
Adjusted (2) Income/(Loss) |
6,050 |
(968) |
* |
14,124 |
9,908 |
43% |
|||||
Adjusted (2) Diluted EPS/(LPS) |
1.06 |
(0.17) |
* |
2.48 |
1.73 |
43% |
|||||
* Indicates calculation not meaningful or results are greater than 100%. |
REVENUES
($ in millions) |
Third-Quarter |
Nine Months |
|||||||
2024 |
2023 |
% Change |
2024 |
2023 |
% Change |
||||
Total |
Oper. |
Total |
Oper. |
||||||
Global Biopharmaceuticals Business (Biopharma) |
$ 17,392 |
$ 13,188 |
32% |
33% |
$ 44,987 |
$ 44,051 |
2% |
3% |
|
Pfizer CentreOne (PC1) |
285 |
293 |
(3%) |
(2%) |
820 |
908 |
(10%) |
(9%) |
|
Pfizer Ignite |
25 |
10 |
* |
* |
56 |
25 |
* |
* |
|
TOTAL REVENUES |
$ 17,702 |
$ 13,491 |
31% |
32% |
$ 45,864 |
$ 44,984 |
2% |
3% |
|
* Indicates calculation not meaningful or results are greater than 100%. |
2024 FINANCIAL GUIDANCE (1)
Pfizer raises full-year 2024 revenue guidance by $1.5 billion at the midpoint to a range of $61.0 to $64.0 billion and raises Adjusted (2) diluted EPS guidance by $0.30 at the midpoint to $2.75 to $2.95. The company's updated guidance for revenue includes approximately $10.5 billion in anticipated revenues for Comirnaty (3) and Paxlovid, approximately $5 billion and $5.5 billion, respectively. Including the contribution from Seagen and excluding revenues from Comirnaty (3) and Paxlovid, Pfizer continues to expect full-year 2024 operational revenue growth of 9% to 11% compared to 2023 revenues; and this growth guidance takes into consideration the reduction of sales associated with the previously announced global withdrawal of Oxbryta.
The updated 2024 Adjusted (2) diluted EPS guidance takes into consideration our strong year-to-date performance as well as our continued confidence in our business.
Pfizer's updated financial guidance (1) is presented below.
Revenues |
$61.0 to $64.0 billion |
(previously $59.5 to $62.5 billion) |
|
Adjusted (2) SI&A Expenses |
$13.8 to $14.8 billion |
Adjusted (2) R&D Expenses |
$11.0 to $12.0 billion |
Effective Tax Rate on Adjusted (2) Income |
Approximately 13.0% |
Adjusted (2) Diluted EPS |
$2.75 to $2.95 |
(previously $2.45 to $2.65) |
Changes in foreign exchange rates have had a minimal incremental impact since full-year 2024 guidance was updated on July 30, 2024. Please refer to Press Release Footnote (1) for additional information.
CAPITAL ALLOCATION
During the first nine months of 2024, Pfizer deployed its capital in a variety of ways, which primarily include the following two categories:
No share repurchases were completed to date in 2024. As of October 29, 2024, Pfizer's remaining share repurchase authorization is $3.3 billion. Current financial guidance does not anticipate any share repurchases in 2024.
Third-quarter 2024 diluted weighted-average shares outstanding used to calculate Reported (4) and Adjusted (2) diluted EPS were 5,705 million shares. For the third quarter of 2023, basic weighted-average shares outstanding of 5,646 million were used to calculate Reported (4) and Adjusted (2) diluted LPS.
QUARTERLY FINANCIAL HIGHLIGHTS (Third-Quarter 2024 vs. Third-Quarter 2023)
Third-quarter 2024 revenues totaled $17.7 billion, an increase of $4.2 billion, or 31%, compared to the prior-year quarter, reflecting an operational increase of $4.3 billion, or 32%, primarily due to growth contributions from Paxlovid as well as several of our acquired products, key in-line products, and recent commercial launches, partially offset by an unfavorable impact of foreign exchange of $133 million, or 1%. Excluding contributions from Paxlovid and Comirnaty (3) , revenues totaled $13.6 billion, an increase of $1.7 billion, or 14%, operationally compared with the prior-year quarter.
Third-quarter 2024 Paxlovid revenues of $2.7 billion increased $2.5 billion operationally compared with the prior-year quarter, primarily due to strong demand, particularly in the U.S., driven by higher utilization during a recent global COVID-19 wave; the one-time contractual delivery of one million treatment courses to the U.S. Strategic National Stockpile in the third quarter of 2024 that accounted for $442 million in revenue; and no U.S. sales in the prior-year quarter in anticipation of the transition to commercial markets in November 2023.
Third-quarter 2024 Comirnaty (3) revenues of $1.4 billion increased $119 million, or 9%, operationally compared with the prior-year quarter, driven primarily by timing of stocking as a result of earlier approval of the new variant vaccine in the U.S. in 2024 compared to 2023, partially offset by lower contractual deliveries and demand in international markets.
Excluding contributions from Comirnaty (3) and Paxlovid, third-quarter 2024 operational revenue growth was driven primarily by:
partially offset primarily by lower revenues for:
GAAP Reported (4) Statement of Operations Highlights
SELECTED REPORTED (4) COSTS AND EXPENSES
($ in millions) |
Third-Quarter |
Nine Months |
||||||||||
2024 |
2023 |
% Change |
2024 |
2023 |
% Change |
|||||||
Total |
Oper. |
Total |
Oper. |
|||||||||
Cost of Sales (4) |
$ 5,263 |
$ 9,269 |
(43%) |
(43%) |
$ 11,942 |
$ 17,391 |
(31%) |
(30%) |
||||
Percent of Revenues |
29.7% |
68.7% |
N/A |
N/A |
26.0% |
38.7% |
N/A |
N/A |
||||
SI&A Expenses (4) |
3,244 |
3,281 |
(1%) |
- |
10,456 |
10,196 |
3% |
3% |
||||
R&D Expenses (4) |
2,598 |
2,711 |
(4%) |
(4%) |
7,787 |
7,864 |
(1%) |
(1%) |
||||
Acquired IPR&D Expenses (4) |
13 |
67 |
(80%) |
(80%) |
20 |
122 |
(84%) |
(84%) |
||||
Other (Income)/Deductions-net (4) |
243 |
181 |
34% |
57% |
2,030 |
381 |
* |
* |
||||
Effective Tax Rate on Reported (4) Income/(Loss) |
5.0% |
28.8% |
4.9% |
(6.2%) |
||||||||
* Indicates calculation not meaningful or results are greater than 100%. |
Third-quarter 2024 Cost of Sales (4) as a percentage of revenues decreased by 39.0 percentage points compared to the prior-year quarter, driven primarily by the non-recurrence of a non-cash charge of $5.6 billion recorded in the third quarter of 2023 for inventory write-offs and related charges ($4.7 billion for Paxlovid and $0.9 billion for Comirnaty (3) ).
Third-quarter 2024 SI&A Expenses (4) were relatively flat operationally compared with the prior-year quarter, reflecting a decrease due to lower U.S. healthcare reform fees primarily related to Paxlovid and Comirnaty (3) , largely offset by an increase in spending related to marketing and promotional expenses for recently launched and acquired products.
Third-quarter 2024 R&D Expenses (4) decreased 4% operationally compared with the prior-year quarter, driven primarily by lower spending on certain ongoing vaccine programs and, to a lesser extent, lower spending as a result of our cost realignment program, partially offset by a net increase in spending mainly to develop certain product candidates acquired from Seagen.
The unfavorable period-over-period change in Other deductions-net (4) of $62 million for the third quarter of 2024, compared with the prior-year quarter, was driven primarily by higher net interest expense and a charge in the third quarter of 2024 related to the expected sale of one of our facilities resulting from the discontinuation of our Duchenne muscular dystrophy (DMD) program, partially offset by net gains on equity securities in the third quarter of 2024 versus net losses on equity securities in the prior-year quarter.
Pfizer's effective tax rate on Reported (4) income for the third quarter of 2024 is primarily a result of its jurisdictional mix of earnings. Pfizer's positive effective tax rate for the third quarter of 2023 reflects a tax benefit on a pre-tax Reported (4) loss.
Adjusted (2) Statement of Operations Highlights
SELECTED ADJUSTED (2) COSTS AND EXPENSES
($ in millions) |
Third-Quarter |
Nine Months |
||||||||||
2024 |
2023 |
% Change |
2024 |
2023 |
% Change |
|||||||
Total |
Oper. |
Total |
Oper. |
|||||||||
Adjusted (2) Cost of Sales |
$ 4,874 |
$ 8,906 |
(45%) |
(45%) |
$ 10,678 |
$ 16,723 |
(36%) |
(35%) |
||||
Percent of Revenues |
27.5% |
66.0% |
N/A |
N/A |
23.3% |
37.2% |
N/A |
N/A |
||||
Adjusted (2) SI&A Expenses |
3,219 |
3,205 |
- |
1% |
10,342 |
9,974 |
4% |
4% |
||||
Adjusted (2) R&D Expenses |
2,561 |
2,679 |
(4%) |
(4%) |
7,708 |
7,797 |
(1%) |
(1%) |
||||
Adjusted (2) Other (Income)/Deductions-net |
243 |
(128) |
* |
* |
797 |
(730) |
* |
* |
||||
Effective Tax Rate on Adjusted (2) Income/(Loss) |
10.8% |
22.3% |
13.3% |
10.4% |
||||||||
* Indicates calculation not meaningful or results are greater than 100%. |
See the reconciliations of certain Reported (4) to non-GAAP Adjusted (2) financial measures and associated footnotes in the financial tables section of this press release located at the hyperlink below.
RECENT NOTABLE DEVELOPMENTS (Since July 30, 2024)
Product Developments
Product/Project |
Recent Development |
Link |
Abrysvo (respiratory syncytial virus vaccine) |
October 2024. Announced the U.S. Food and Drug Administration (FDA) approved Abrysvo for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 18 through 59 years of age who are at increased risk for LRTD caused by RSV. Abrysvo now offers the broadest RSV vaccine indication for adults, which previously included those 60 years and older. Additionally, it remains the only RSV immunization approved for pregnant individuals at 32 through 36 weeks of gestation to protect infants from birth up to 6 months of age. |
|
August 2024. Announced positive top-line safety and immunogenicity results from substudy B of the pivotal Phase 3 clinical trial (NCT05842967) MONeT (RSV IMmunizatiON Study for AdulTs at Higher Risk of Severe Illness), evaluating two doses of Abrysvo vaccine in immunocompromised adults aged 18 and older at risk of developing severe RSV-associated LRTD. Results showed Abrysvo was well-tolerated and generated strong neutralizing responses after a single 120 µg dose in adults ≥ 18 years of age. |
||
Braftovi (encorafenib) + Mektovi (binimetinib) |
September 2024. Presented longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of Braftovi in combination with Mektovi for patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology (ESMO) Congress 2024, in which the combination of Braftovi + Mektovi continued to show substantial antitumor activity after a minimum follow up of approximately three years, and while there are no head-to-head studies, this corresponds to the longest duration of response and progression-free survival in treatment-naïve patients compared to historical outcomes. |
|
Comirnaty (3) (COVID-19 Vaccine, mRNA) |
September 2024. Announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended marketing authorization for Pfizer and BioNTech's Omicron KP.2-adapted monovalent COVID-19 vaccine (Comirnaty KP.2) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. Subsequently, the European Commission (EC) authorized the vaccine on September 27, 2024. |
|
August 2024. Announced the FDA approved the supplemental Biologics License Application for Pfizer and BioNTech's Comirnaty (3) for individuals 12 years of age and older and granted emergency use authorization for individuals 6 months through 11 years of age both for the companies' Omicron KP.2-adapted 2024-2025 Formula COVID-19 vaccine. |
||
Eliquis |
August 2024. Announced the U.S. Department of Health and Human Services released the "maximum fair price" (MFP) for Eliquis, which was selected in the first round of government price setting as part of the Inflation Reduction Act (IRA). The imposed MFP for a 30-day equivalent supply of Eliquis, which is the price that Medicare will pay for Eliquis as of January 1, 2026, is $231. |
|
Hympavzi |
October 2024. Announced the FDA approved Hympavzi for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and pediatric patients 12 years of age and older with hemophilia A (congenital factor VIII deficiency) without factor VIII (FVIII) inhibitors, or hemophilia B (congenital factor IX deficiency) without factor IX (FIX) inhibitors. Hympavzi is Pfizer's second hemophilia treatment to receive FDA approval this year. |
|
September 2024. Announced the CHMP of the EMA adopted a positive opinion for marstacimab for the routine prophylaxis of bleeding episodes in adults and adolescents 12 years and older with severe hemophilia A (congenital factor VIII [FVIII] deficiency, FVIII <1%) without FVIII inhibitors, or severe hemophilia B (congenital factor IX [FIX] deficiency, FIX <1%) without FIX inhibitors. |
||
Oxbryta |
September 2024. Announced the voluntary withdrawal of all lots of Oxbryta for the treatment of sickle cell disease (SCD) in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide. The decision is based on the totality of clinical data that now indicates the overall benefit of Oxbryta no longer outweighs the risk in the approved sickle cell patient population. The data suggest an imbalance in vaso-occlusive crises and fatal events, which requires further assessment. |
|
Prevnar 20 (20-valent pneumococcal conjugate vaccine) |
October 2024. Announced the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practice (ACIP) voted to expand its recommendation for the use of certain pneumococcal vaccines, including Prevnar 20 for all adults aged 50 and older and for adults aged 19-49 years with certain underlying conditions or risk factors who have not received a pneumococcal conjugate vaccine (PCV) or whose vaccination history is unknown. This recommendation is pending final approval by the director of the CDC and the Department of Health and Human Services. |
|
Talzenna |
October 2024. Announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna, an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor (ARPI), in patients with metastatic castration-resistant prostate cancer (mCRPC). Results showed a statistically significant and clinically meaningful improvement in the final OS in all-comers (cohort 1) as well as in those patients with homologous recombination repair (HRR) gene-mutated mCRPC (cohort 2), compared to Xtandi alone. These data will be shared with global health authorities and detailed results submitted for presentation at an upcoming medical congress. |
Pipeline Developments
A comprehensive update of Pfizer's development pipeline was published today and is now available at www.pfizer.com/science/drug-product-pipeline. It includes an overview of Pfizer's research and a list of compounds in development with targeted indication and phase of development, as well as mechanism of action for some candidates in Phase 1 and all candidates from Phase 2 through registration.
Product/Project |
Recent Development |
Link |
Combination COVID-19 and Influenza vaccine candidate |
August 2024. Announced Phase 3 top-line results for Pfizer and BioNTech's combination mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age. The trial did not meet one of its primary immunogenicity objectives of non-inferiority against the influenza B strain despite obtaining higher influenza A responses and comparable COVID-19 responses versus the comparator vaccines. The companies are evaluating adjustments to the candidate and are discussing next steps with health authorities. |
|
ponsegromab |
September 2024. Presented data from the Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), in people with cancer cachexia and elevated levels of GDF-15 at ESMO Congress 2024. The data were also simultaneously published in The New England Journal of Medicine . The study met its primary endpoint of change from baseline in body weight for ponsegromab compared to placebo across all ponsegromab doses tested, reaching 5.6% mean increase at the highest dose evaluated at 12 weeks. At the highest dose evaluated, improvements were seen from baseline in appetite and cachexia symptoms, physical activity, and muscle mass. Ponsegromab was generally considered safe and well-tolerated at all dose levels in the study. Pfizer is discussing late-stage development plans with regulators with the goal of starting registration-enabling studies in 2025. Ponsegromab is also being investigated in a Phase 2 study in patients with heart failure and elevated serum GDF-15 concentrations (NCT05492500). |
|
Trivalent Influenza vaccine candidate |
August 2024. Announced data from a Phase 2 trial with second-generation trivalent (tIRV) influenza mRNA vaccine candidates which showed encouraging data demonstrating robust immunogenicity in individuals 18-64 years of age. The tIRV formulations elicited robust influenza A and B responses, including continued trend of higher influenza A responses versus a licensed influenza vaccine. No safety signals were reported in the trial. Pfizer will continue to evaluate its influenza vaccine program and discuss next steps with health authorities. |
|
VLA15 (Lyme vaccine candidate) |
September 2024. Valneva and Pfizer announced positive immunogenicity and safety data from a Phase 2 study following a second booster vaccination of their Lyme disease vaccine candidate, VLA15, given one year after receiving the first booster dose. The immune response and safety profile of VLA15 one month after receiving the second booster dose were similar to those reported after receiving the first booster dose, showing compatibility with the anticipated benefit of a booster vaccination prior to each Lyme season. There are currently no approved human vaccines for Lyme disease, and VLA15 is the Lyme disease vaccine candidate which has advanced the furthest along the clinical development timeline, with two Phase 3 trials in progress. |
Corporate Developments
Topic |
Recent Development |
Link |
Board Election |
October 2024. Announced Tim Buckley was elected to Pfizer's Board of Directors. Mr. Buckley was also appointed to and will join the Governance and Sustainability Committee and the Audit Committee of Pfizer's Board of Directors. |
|
Haleon Stock Sale |
October 2024. Pfizer sold 640 million ordinary shares of its investment in Haleon to institutional investors and sold 60.5 million Haleon ordinary shares directly to Haleon for total net consideration of approximately $3.5 billion. After the share sale, Pfizer's ownership interest in Haleon was reduced from approximately 23% to approximately 15%. |
N/A |
"PfizerForAll" |
August 2024. Introduced PfizerForAll™, a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across the U.S. The new, end-to-end experience will support Americans affected by common illnesses like migraine, COVID-19 or flu and those seeking to protect themselves with adult vaccinations. By bringing together critical resources and services into a single destination, PfizerForAll helps individuals and their families cut down on the time and steps needed to take important health actions like getting care, filling prescriptions, and finding potential savings on Pfizer medicines. |
Please find Pfizer's press release and associated financial tables, including reconciliations of certain GAAP reported to non-GAAP adjusted information, at the following hyperlink:
https://investors.pfizer.com/Q3-2024-PFE-Earnings-Release
(Note: If clicking on the above link does not open a new webpage, you may need to cut and paste the above URL into your browser's address bar.)
For additional details, see the attached financial schedules and product revenue tables attached to the press release located at the hyperlink above, and the attached disclosure notice.
(1) |
Pfizer does not provide guidance for GAAP Reported financial measures (other than revenues) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP Reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of unusual gains and losses, certain acquisition-related expenses, gains and losses from equity securities, actuarial gains and losses from pension and postretirement plan remeasurements, potential future asset impairments and pending litigation without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP Reported results for the guidance period. |
|
Financial guidance for full-year 2024 reflects the following: |
||
|
||
|
||
|
||
|
||
|
||
(2) |
Adjusted income/(loss) and Adjusted diluted EPS/(LPS) are defined as U.S. GAAP net income/(loss) attributable to Pfizer Inc. common shareholders and U.S. GAAP diluted EPS/(LPS) attributable to Pfizer Inc. common shareholders before the impact of amortization of intangible assets, certain acquisition-related items, discontinued operations and certain significant items. See the reconciliations of certain GAAP Reported to Non-GAAP Adjusted information for the third quarter and the first nine months of 2024 and 2023 in the press release located at the hyperlink above. Adjusted income/(loss) and its components and Adjusted diluted EPS/(LPS) measures are not, and should not be viewed as, substitutes for U.S. GAAP net income/(loss) and its components and diluted EPS/(LPS) (4) . See the Non-GAAP Financial Measure: Adjusted Income section of Management's Discussion and Analysis of Financial Condition and Results of Operations in Pfizer's 2023 Annual Report on Form 10-K and the accompanying Non-GAAP Financial Measure: Adjusted Income/(Loss) section of the press release located at the hyperlink above for a definition of each component of Adjusted income/(loss) as well as other relevant information. |
|
(3) |
As used in this document, "Comirnaty" refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine; Comirnaty (COVID-19 Vaccine, mRNA) original monovalent formula; the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5); the Pfizer-BioNTech COVID-19 Vaccine (2023-2024 Formula); Comirnaty (COVID-19 Vaccine, mRNA) 2023-2024 Formula; Comirnaty (COVID-19 Vaccine, mRNA) 2024-2025 Formula; Comirnaty Original/Omicron BA.1; Comirnaty Original/Omicron BA.4/BA.5; Comirnaty Omicron XBB.1.5; Comirnaty JN.1 and Comirnaty KP.2. "Comirnaty" includes product revenues and alliance revenues related to sales of the above-mentioned vaccines. |
|
(4) |
Revenues is defined as revenues in accordance with U.S. generally accepted accounting principles (GAAP). Reported net income/(loss) and its components are defined as net income/(loss) attributable to Pfizer Inc. common shareholders and its components in accordance with U.S. GAAP. Reported diluted earnings per share (EPS) and reported diluted loss per share (LPS) are defined as diluted EPS or LPS attributable to Pfizer Inc. common shareholders in accordance with U.S. GAAP. |
|
(5) |
The targeted $4 billion in net cost savings is calculated versus the midpoint of Pfizer's 2023 SI&A and R&D expense guidance provided on August 1, 2023. As an additional reference, see the '2024 Financial Guidance' section of Pfizer's fourth-quarter 2023 earnings release. |
|
(6) |
References to operational variances in this press release pertain to period-over-period changes that exclude the impact of foreign exchange rates. Although foreign exchange rate changes are part of Pfizer's business, they are not within Pfizer's control and because they can mask positive or negative trends in the business, Pfizer believes presenting operational variances excluding these foreign exchange changes provides useful information to evaluate Pfizer's results. |
|
(7) |
Pfizer's fiscal year-end for international subsidiaries is November 30 while Pfizer's fiscal year-end for U.S. subsidiaries is December 31. Therefore, Pfizer's third quarter and first nine months for U.S. subsidiaries reflects the three and nine months ended on September 29, 2024 and October 1, 2023, while Pfizer's third quarter and first nine months for subsidiaries operating outside the U.S. reflects the three and nine months ended on August 25, 2024 and August 27, 2023. |
DISCLOSURE NOTICE: Except where otherwise noted, the information contained in this earnings release and the related attachments is as of October 29, 2024. We assume no obligation to update any forward-looking statements contained in this earnings release and the related attachments as a result of new information or future events or developments.
This earnings release and the related attachments contain forward-looking statements about, among other topics, our anticipated operating and financial performance, including financial guidance and projections; reorganizations; business plans, strategy, goals and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, launches, clinical trial results and other developing data, revenue contribution and projections, potential pricing and reimbursement, potential market dynamics, including demand, market size and utilization rates and growth, performance, timing of exclusivity and potential benefits; strategic reviews; capital allocation objectives; an enterprise-wide cost realignment program, which we launched in October 2023 (including anticipated costs, savings and potential benefits); a Manufacturing Optimization Program to reduce our cost of goods sold, which we announced in May 2024 (including anticipated costs, savings and potential benefits); dividends and share repurchases; plans for and prospects of our acquisitions, dispositions and other business development activities, including our December 2023 acquisition of Seagen, and our ability to successfully capitalize on growth opportunities and prospects; manufacturing and product supply; our ongoing efforts to respond to COVID-19, including our plans and expectations regarding Comirnaty (as defined in this earnings release) and our oral COVID-19 treatment (Paxlovid); our expectations regarding the impact of COVID-19 on our business, operations and financial results; and our Environmental, Social and Governance (ESG) priorities, strategies and goals. Given their forward-looking nature, these statements involve substantial risks, uncertainties and potentially inaccurate assumptions and we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. You can identify these statements by the fact that they use future dates or use words such as "will," "may," "could," "likely," "ongoing," "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "assume," "target," "forecast," "guidance," "goal," "objective," "aim," "seek," "potential," "hope" and other words and terms of similar meaning. Pfizer's financial guidance is based on estimates and assumptions that are subject to significant uncertainties.
Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following:
Risks Related to Our Business, Industry and Operations, and Business Development:
Risks Related to Government Regulation and Legal Proceedings:
Risks Related to Intellectual Property, Technology and Security:
Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and in our subsequent reports on Form 10-Q, in each case including in the sections thereof captioned "Forward-Looking Information and Factors That May Affect Future Results" and "Item 1A. Risk Factors," and in our subsequent reports on Form 8-K.
This earnings release may include discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.
The information contained on our website or any third-party website is not incorporated by reference into this earnings release. All trademarks mentioned are the property of their owners.
Certain of the products and product candidates discussed in this earnings release are being co-researched, co-developed and/or co-promoted in collaboration with other companies for which Pfizer's rights vary by market or are the subject of agreements pursuant to which Pfizer has commercialization rights in certain markets.
Media
[email protected]
212.733.1226
Investors
[email protected]
212.733.4848